Close

Kamada Ltd. (KMDA) Reports Top-line Results from Phase 1/2 Clinical Trial of Plasma-Derived Hyperimmune Globulin Treatment for COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BA
8. SNAP
9. TMUS
10. BSX


Go back to Kamada Ltd. (KMDA) Reports Top-line Results from Phase 1/2 Clinical Trial of Plasma-Derived Hyperimmune Globulin Treatment for COVID-19
KAMADA LTD (NASDAQ: KMDA) Delayed: 5.20 +0.02 (0.39%)
Previous Close $5.18    52 Week High $6.29 
Open $5.13    52 Week Low $3.26 
Day High $5.20    P/E N/A 
Day Low $5.12    EPS $0.00 
Volume 10,500